Wisp and Mount Sinai Launch Fully Remote PrEP Program Five Months After Acquisition

Wisp and the Mount Sinai Health System announced a fully remote HIV prevention program on June 9. The partnership embeds Wisp's telehealth platform inside Mount Sinai's clinical infrastructure, enabling patients to start PrEP entirely online, complete quarterly testing with at-home kits, and receive prescriptions within 24 to 48 hours of lab results.

PrEP reduces the risk of HIV transmission by 99% when taken as directed.

2 million Americans could benefit from the medication, yet only 36% of those eligible have ever been prescribed it. In New York City, 1,791 people received a new HIV diagnosis in 2024, the majority among Black, Latino, or gay individuals. Women account for nearly 20% of new HIV diagnoses nationwide but remain less likely to take PrEP than men.

Mount Sinai launched a hybrid tele-PrEP program through its Institute for Advanced Medicine in 2022. That earlier effort still required patients to visit a clinic for quarterly lab work. The new collaboration removes that requirement by integrating Wisp's platform with Mount Sinai's records through Epic, creating a shared patient record that supports fully remote, hybrid, or in-person care.

Wisp's platform handles consult, clinical review, and discreet delivery of PrEP. The company uses a subscription model that ships at-home test kits at required intervals along with check-ins and follow-ups. Commercial insurance coverage brings the cost to $0 for 99% of Wisp patients.

U.S. PrEP users, more than 110,000 people, accessed the medication via telemedicine in 2024. 8 million patients who are predominantly women. Monica Cepak, CEO of Wisp, said the company speaks to women differently than to the male community because it is a different audience with different needs.